Iterum Therapeutics plc has announced that its ordinary shares will be delisted from The Nasdaq Stock Market LLC effective April 1, 2026. This decision follows the company's withdrawal of its appeal against a prior delisting determination due to its failure to maintain a minimum bid price of $1.00 per share. The company had previously received a delisting determination letter on February 24, 2026, and requested a hearing to contest this decision. However, on March 27, 2026, Iterum filed a petition in the High Court in Ireland to wind up the company, which led to the withdrawal of its appeal. As a result, Nasdaq has confirmed that trading of the company's shares will be suspended, and a Form 25-NSE will be filed with the Securities and Exchange Commission (SEC) to officially remove the shares from listing. Given the company's limited cash resources and ongoing winding up process, it does not expect to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, nor make any future filings with the SEC. This situation reflects significant challenges for Iterum, as it navigates the complexities of its financial and operational status amidst the winding up process.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.